NUVL
Nuvalent, Inc.
$101.74
-2.19
(-2.11%)
| Exchange: | |
| Market Cap: | 7.397B |
| Shares Outstanding: | 48.284M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | James R. Porter | |||||
| Full Time Employees: | 162 | |||||
| Address: |
|
|||||
| Website: | https://www.nuvalent.com |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
